Patients prefer dropless medication after cataract surgery

Patients preferred dropless medication following cataract surgery, according to study data presented at the 2020 ASCRS Virtual Meeting.

In this study, patient experience with a dropless medication, including insert dexamethason, intracameral ketorolac and moxifloxacin, or usual drops after bilateral sequential cataract surgery 2 weeks apart were compared.

After 2 months, approximately 96% of patients said they preferred the eye that used no drops. Between the 2 groups, there was no significant difference in inflammation at 14 days.

The mean out-of-pocket cost to patients for treatment in the dropless and control groups were $26 and $184, respectively.

Reference
Donnenfeld ED, Hovanesian JA, Shojaei R, et al. Dropless punctual insert dexamethason, intracameral ketorolac and moxifloxacin compared to conventional topical therapy in cataract surgery. Presented at: 2020 ASCRS Virtual Meeting.